Wanjia Group Holdings (HKG:0401) expects to record up to HK$1.5 million in profit attributable to owners for the six months ended Sept. 30, rebounding from a loss of HK$3.0 million a year ago.
The pharmaceutical distribution company attributed the turnaround to improvements in its hemodialysis treatment and consultancy service business segments in China, according to a Wednesday disclosure with the Hong Kong Exchange.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.